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Abstract
Hypertension is a major health problem of largely unknown genetic origins. To identify new genes responsible for
hypertension, genetic analysis of recombinant inbred strains of mice followed by human association studies might prove
powerful and was exploited in our current study. Using a set of 27 recombinant BXD strains of mice we identified a
quantitative trait locus (QTL) for blood pressure (BP) on distal chromosome 9. The association analysis of markers
encompassing the syntenic region on human chromosome 3 gave in an additive genetic model the strongest association
for rs17030583 C/T and rs2291897 G/A, located within the UBP1 locus, with systolic and diastolic BP (rs17030583:
1.360.4 mmHg p,0.001, 0.860.3 mmHg p=0.006, respectively and rs2291897: 1.560.4 mmHg p,0.001, 0.860.3 mmHg
p=0.003, respectively) in three separate studies. Our study, which underscores the marked complementarities of mouse
and human genetic approaches, identifies the UBP1 locus as a critical blood pressure determinant. UBP1 plays a role in
cholesterol and steroid metabolism via the transcriptional activation of CYP11A, the rate-limiting enzyme in pregnenolone
and aldosterone biosynthesis. We suggest that UBP1 and its functional partners are components of a network controlling
blood pressure.
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Introduction
Elevated arterial blood pressure is a major health problem
accounting for a large proportion of cardiovascular morbidity and
mortality world-wide. It is estimated that over one billion people
are hypertensive, and its prevalence is continuously increasing [1].
Elevated BP is a major risk factor for the development of
cardiovascular disease, including coronary heart disease, conges-
tive heart failure, ischemic and hemorrhagic stroke, renal failure,
and peripheral arterial disease [2]. BP is modulated by both
genetic and environmental factors, including NaCl intake, alcohol
consumption, physical inactivity, and stress. Several genes
responsible for rare Mendelian forms of hypertension have been
identified (CYP11B1, CYP11B2, HSD11B1, MR, SCNN1B,
SCNN1G, WNK1, WNK4) and shown to play a significant role in
the renal control of BP [3–9]. In addition, rare independent
mutations in salt handling genes SLC2A3, SLC12A1 and KCNJ1
have been shown to reduce BP and protect from the development
of hypertension [10]. However, common genetic variants that are
associated with BP remain to be identified.
Using a set of recombinant BXD strains of mice we identified a
quantitative trait locus for blood pressure. To validate the role of
this QTL in blood pressure control in man we used an association
analysis of markers encompassing the syntenic region in humans
and confirmed UBP1 locus as a critical blood pressure determi-
nant.
Results
We have exploited a genetic reference panel of recombinant
inbred strains of mice to map chromosomal regions that influence
blood pressure under tightly controlled baseline laboratory
PLoS Genetics | www.plosgenetics.org 1 August 2009 | Volume 5 | Issue 8 | e1000591conditions. We measured systolic BP in a panel of 27 male and 21
female BXD recombinant inbred mouse strains [11], all from the
new series of strains (BXD43 through BXD103). These strains
have all been genotyped using a high density panel of single
nucleotide polymorphisms (SNPs) [11] and this set can provide up
to twice the mapping resolution of an equal number of
conventional recombinant inbred strains.
BP varied widely across BXD strains (Figure 1A); from a low of
81.765.4 mmHg to a high of 128.3611.4 mmHg. These strain
differences were common to both sexes and the correlation
between sexes was 0.86. We performed a QTL mapping of systolic
BP using GeneNetwork (www.genenetwork.org, see BXD pheno-
type database IDs 11017 and 12076 for males and females,
respectively). A significant QTL modulating BP was detected on
Chr 9 between approximately 111.0 and 114.2 Mb (2-LOD CI,
genome-wide p,.05), with a peak likelihood ratio statistics (LRS)
of 21.6 (LOD=4.7) in the interval between 113.2 and 113.9 Mb
in the males (Figure 1B and 1C). The same interval also generated
the highest genome-wide linkage in the smaller female sample
(n=21 strains), and the LRS was more modest.
The mouse BP QTL covers a genomic region of unusually low
gene density (Figure 1C) that includes the Pdcd6ip, Clasp2, Ubp1,
and Fbxl2 genes within the QTL. PDCD6IP is a ubiquitously
expressed protein that plays a role in apoptosis, virus budding,
multivesicular bodies cargo sorting and cell surface receptor down
regulation [12–16]. PDCD6IP interacts with vasopressin receptor
V2R and when overexpressed, increases the lysosomal degrada-
Author Summary
To identify new genes responsible for hypertension, a
major health problem, we performed a genetic analysis of
recombinant inbred strains of mice followed by human
association studies. Using a set of 27 recombinant BXD
strains of mice, we identified a quantitative trait locus for
blood pressure (BP) on distal chromosome 9 encompass-
ing the UBP1 gene locus. In three subsequent human
genetic studies, the syntenic locus was shown to be
associated with systolic and diastolic BP, identifying the
UBP1 locus as a critical blood pressure determinant. UBP1
is a transcription factor, known to control the expression of
CYP11A, the rate-limiting enzyme in pregnenolone and
aldosterone biosynthesis, suggesting that it controls blood
pressure via this pathway. Our study furthermore under-
scores the marked complementarities of mouse and
human genetic approaches
Figure 1. Mapping of a systolic blood pressure (SBP) quantitative trait locus (QTL) in BXD strains. (A) Rank ordered mean BP values
across 27 male and 21 female BXD strains (with SEM error bars). (B) In males, a significant BP QTL is mapped on chromosome 9. In females, BP QTL
maps to the same region on chromosome 9. (C) The genomic region corresponding to the BP QTL on chromosome 9. The LOD score is depicted in
blue with the highest values at the position 113.2 to 113.9 Mb achieving LOD of 4.7. Individual genes under the BP QTL peak are indicated. (D) The
syntenic chromosomal region in human.
doi:10.1371/journal.pgen.1000591.g001
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candidate gene. It is microtubule plus-end tracking protein that
plays a role in microtubule dynamics [17]. At present, no link
exists between CLASP2 function and BP. Ubp1, also termed LBP1-
a or NF2D9, is the third candidate gene within the BP QTL. It is
an ubiquitously expressed member of the grainyhead transcription
factor family [18]. The null allele of the mouse Ubp1 gene is lethal
during early embryogenesis due to placenta insufficiency attribut-
able to a defect in extraembryonic angiogenesis [19]. The last
candidate gene, FBXL2 belongs to the FBL family of proteins that
facilitate ubiquitination of the substrate proteins.
To efficiently evaluate the strength of these four candidates we
opted to study single nucleotide polymorphisms in human cohorts
for which excellent data on BP are already available as part of the
EUGENE2 cohort (N=867) [20]. Initial marker screening was
directed to the genomic location indicated by the analysis of the
BXD mouse lines (human chromosome 3, 33.2–33.9 Mb region).
A total of 290 markers were located in this region (73 SNPs
directly genotyped, 217 imputed). Association analysis for both
systolic BP and diastolic BP was performed for these markers. Two
SNPs in the region of UBP1-FBXL2 gave the strongest association
(rs17030583, UBP1, intron 11, C/T; rs2291897, FBXL2, intron
11, G/A; Figure 2, Table 1). We also analyzed the results in 788
participants of the EUGENE2 study without antihypertensive
treatment. The associations of rs17030583 and rs2291897 with
SBP (P 0.010 and 0.011, respectively) and DBP (P 0.069 and
0.172, respectively) remained essentially similar as in the entire
EUGENE2 cohort given the smaller sample size. The associations
with these SNPs were replicated in two other cohorts, the Finnish
METSIM (Metabolic Syndrome In Men) (N=2537) [21] and the
German RIAD (Risk factors in Impaired glucose tolerance for
Atherosclerosis and Diabetes) (N=237) (Table 1) [22]. Since the
age range of subjects in the EUGENE2 study was #55 years, we
restricted statistical analyses of the replication cohorts also to the
same age category.
We observed statistically significant associations of systolic and
diastolic BP with these two SNPs under the additive model
(Table 1). SNP rs2291897 (G/A) in the pooled data was
significantly associated with systolic (P=0.00036) and diastolic
BP (P=0.0030). The pooled effect size of this SNP was 1.5 (0.4) for
systolic and 0.8 (0.3) mmHg with diastolic BP. Similarly,
rs17030538 (C/T) was associated with systolic (P=0.00099) and
diastolic BP (P=0.00036), with pooled effect size of 1.3 (0.4) for
systolic and 0.8 (0.3) mmHg with diastolic BP. We also determined
the association of rs17030583 and rs2291897 with BP levels in the
entire cohort of the METSIM Study (N=7422) (rs17030583, P
values of 0.510 and 0.773 for an association with systolic and
diastolic BP, respectively; rs2291897, P values of 0.333 and 0.362
for an association with systolic and diastolic BP, respectively) and
RIAD Study (N=617) (rs17030583, P values of 0.107 and 0.191
for an association with systolic and diastolic BP, respectively;
rs2291897, P values of 0.420 and 0.049 for an association with
systolic and diastolic BP, respectively), and found no association
with BP levels. The lack of association was limited to the age range
.55 years, and was explained by a very strong interaction of
rs17030583 and rs2291897 with age on their effects on systolic BP
(rs2291897: METSIM Study P=6.4610
287, RIAD Study
P=7.3610
24).
Discussion
We have mapped an interval on chromosome 9 between 113.2
and 113.9 Mb as contributing to the BP variation in a BXD panel
of mice. The relatively small size of this chromosomal region can
be explained by a high frequency of recombination achieved in the
recombinant inbred mouse lines.
The identified mouse chromosome 9 band F3 (9F3) region is
syntenic to rat chromosome 8q32 to which a BP QTL was
previously mapped [23]. The corresponding human chromosome
band is 3p22.3, remarkably enough also within a known
susceptibility locus for arterial pulse pressure—the difference
between systolic BP and diastolic BP [24]. These data indicate that
in three species an orthologous region modulates BP.
Our SNP analysis of the syntenic region in humans (human
chromosome 3, 33.2–33.9 Mb region) revealed that rs17030583,
UBP1, intron 11, C/T and rs2291897, FBXL2, intron 11, G/A
gave the most significant P values for an association with BP levels
under the additive model in the EUGENE2 Study. The FBXL2/
UBP1 gene locus (Figure 3) belongs to a haploblock including also
other genes (CLASP2, PDC61P, SUSD5). Therefore, we genotyped
in the METSIM cohort those SNPs of CLASP2 (rs9841066),
PDC61P (rs9311032, rs9858195), and SUSD5 (rs4678778,
rs9836433, rs10222597) which gave the most significant P values
in the EUGENE2 Study. We did not find any significant
associations of these SNPs either with systolic or diastolic BPs in
the METSIM Study suggesting that the FBXL2/UBP1 locus
represents the best association signal with systolic and diastolic BPs
from that gene region. SNP rs2291897 is located on Chr 3
(position 33394426) in intron 11 of FBXL2, and is almost in
complete linkage disequilibrium (99.6%) with rs2272152 located
23 bp from the acceptor site of exon 4 of UBP1. Because we also
found a significant association of rs17030583 of UBP1 with systolic
BP it is likely that our findings in the haploblock are explained by a
signal from the FBXL2/UBP1 region (linkage disequilibrium
between rs2291897 and rs17030583 was 75% in the EUGENE2
Study). However, we cannot rule out the possibility that our
findings are explained by another gene locus at linkage
disequilibrium with the FBXL2/UBP1 region. It remains to be
determined whether these SNPs are replicated in other popula-
tion-based studies including individuals #55 years and whether
these SNPs have functional consequences on UBP1 splicing and/
or mRNA generation. Two recent meta-analyses did not report an
association of these SNPs with high systolic or diastolic BPs
[25,26], which might be due to higher age range when compared
to our study (,70 years in [25]; ,85 years in [26]). We found a
strong interaction of rs17030583 and rs2291897 with age on their
effects on systolic BP, which might indicate that these associations
are observed only in middle-aged and younger individuals.
UBP1 regulates expression of CYP11A, the gene encoding the
rate-limiting enzyme in steroidogenesis, and is expressed in
placenta and adult adrenals [27]. An adrenal steroid biosynthesis
alteration via CYP11A and the 3b-HSD2, CYP21, CYP11B2
cascade is hypothesized to lead to increased aldosterone secretion,
expanded plasma volume, and hypertension. Furthermore, UBP1
is also expressed in mouse heart and aorta [28] (GEO profiles,
www.ncbi.nlm.nih.gov/sites/entrez). However, the role of
CYP11A, 3b-HSD2, CYP21 and CYP11B2 in human heart and
aorta is a matter of debate [29,30]. If UBP1 could also
transactivate the CYP11A promoter in heart and aorta, UBP1
might drive the cardiac remodeling via control of aldosterone
levels. The closest UBP1 gene homologue, TFCP2L1 (also known
as LBP-9), suppresses CYP11A transcriptional activity in placental
cells [27] and LBP-9 gene-trapped mice die postnatally with a
dramatically decreased expression of kidney salt handling genes or
survive with a mild polyuria and an increased net electrolyte
excretion [31]. The antagonistic actions of LBP-9 and UBP1 on
the CYP11A expression suggests that these two genes could play a
counterbalancing role in blood pressure control. Approaches
UBP1 as a Critical Blood Pressure Determinant
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driven genes could represent novel therapeutic approaches to treat
hypertension and eventually other cardiovascular diseases.
Methods
Blood pressure measurements in the mouse
All animal work was conducted according to French and EU
guidelines. The BXD advanced recombinant inbred mouse strains
were generated by crossing C57BL/6J and DBA/2J mice,
intercrossing progenyfortengenerations withintentional avoidance
of sib mating, and finally inbreeding the advance intercross stock for
more than 20 generations [32]. All mice were 16-weeks-old and
were fed standard rodent chow when phenotyped. The systolic BP
wasmeasured by a computerized tail-cuffsystem (BP-2000,Visitech
Systems, Apex, NC) in conscious animals. Following 10 preliminary
measurements in pre-warmed tail-cuff (36uC) device to accustom
mice to the procedure, 10 actual measurement cycles were collected
Figure 2. Regional association plots of the genomic location indicated by the mouse model in the EUGENE2 human study
population. Associations of SNPs rs17030583 and rs2291897 (blue diamonds) to systolic and diastolic blood pressure are plotted with their P-values
(as 2log10 values) as a function of genomic position (with NCBI build 36). Estimated recombination rates (from Hapmap Phase 3) are plotted to
reflect the local LD structure around the associated SNPs and their correlated proxies (red: r
2$0.8; orange: 0.5#r
2,0.8; gray: 0.2#r
2,0.5; white:
r
2,0.2). Diamonds represent directly genotyped markers and circles represent imputed markers.
doi:10.1371/journal.pgen.1000591.g002
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individual animal. As movement artefact could reduce the number
of successful recording, the daily procedure was considered
successful when 7 out of 10 measurements were valid with a
standard deviation less than 10 mmHg. BP recording was
performed on 5 consecutive days. For each individual, BP mean
of 5 consecutive days was averaged and used for analysis. The BP
was determined using n=1 (10% of BXD strains), n=2 (70%) and
n=4 (20%) of mice per BXD strain.
EUGENE2 genome-wide association study
Participants. The participants included in this study were
healthy, non-diabetic offspring of patients with type 2 diabetes, as
previously described in detail [20]. A total of 466 families were
Table 1. The effects of two SNPs of the UBP1 gene locus on systolic and diastolic blood pressure (BP. mean6SD or SE) in three
different Caucasian cohorts under the additive model.
SNP ID Cohort N
Minor allele
frequency BP. (mmHg)*
Effect size.
(mmHg) (SE) P value
Systolic BP
rs17030583 EUGENE2 867 0.24 123 (17) +2.4 (0.9) 0.006
METSIM 2532 0.3 137 (18) +0.8 (0.5) 0.076
RIAD 237 0.26 131 (17) +3.5 (1.8) 0.063
Pooled 3636 0.29 +1.3 (0.4) 0.00099
rs2291897 EUGENE2 866 0.2 123 (17) +2.8 (0.9) 0.01
METSIM 2537 0.27 137 (18) +1.0 (0.5) 0.028
RIAD 237 0.21 132 (18) +2.2 (2.1) 0.297
Pooled 3640 0.25 +1.5 (0.4) 0.00036
Diastolic BP
rs17030583 EUGENE2 867 0.24 78 (12) +2.1 (0.6) 0.023
METSIM 2532 0.3 90 (11) +0.4 (0.3) 0.136
RIAD 237 0.26 83 (11) +0.9 (1.0) 0.452
Pooled 3636 0.29 +0.8 (0.3) 0.0063
rs2291897 EUGENE2 866 0.2 78 (12) +2.0 (0.7) 0.056
METSIM 2537 0.27 90 (11) +0.6 (0.3) 0.051
RIAD 237 0.21 83 (11) +0.7 (1.2) 0.55
Pooled 3640 0.25 +0.8 (0.3) 0.003
*Systolic and diastolic BP (SD) for the common homozygote.
doi:10.1371/journal.pgen.1000591.t001
Figure 3. Gene and LD block structure of the human chromosome 3. 33.2–33.9 Mb region. Based on the imputed EUGENE2 data. Dark red
color represents perfect LD (R
2) of 1 between the markers.
doi:10.1371/journal.pgen.1000591.g003
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families, two in 106 families, three in 54 families, and four or more
in 41 families). One of the parents had to have type 2 diabetes and
the other parent normal glucose tolerance in an oral glucose
tolerance test and/or no history of type 2 diabetes in the family.
The probands were randomly selected among type 2 diabetic
patients living in the regions of five centers in Europe. They were
recruited over a 4-year period through advertisements in public
media and in the hospitals. The acceptance rate of volunteers was
at least 70% in the different centers. Altogether 869 offspring,
having blood pressure measurements, were included in the study
from the following centers: Copenhagen, Denmark (n=257),
Gothenburg, Sweden (n=134), Kuopio, Finland (n=299) and
Tubingen, Germany (n=179). The appropriate Institutional
Review Boards approved the study protocol. All study
participants gave informed consent.
Measurements. All centers followed the same protocol. BP
was measured with a mercury sphygmomanometer in the sitting
position after a 5 min rest. The average of two measurements was
used in statistical analyses. BP of individuals who were on BP
medication (8.6% of study subjects) was adjusted by adding
15 mmHg to systolic and 10 mmHg to diastolic BP [33]. Height
and weight were measured to the nearest 0.5 cm and 0.1 kg,
respectively and body mass index (BMI, kg/m2) calculated.
Because the primary aim of the EUGENE2 Study was to
investigate the genes associated with insulin secretion and insulin
sensitivity every participant underwent detailed metabolic studies,
as described [20].
Sample preparation, genotyping, and quality control.
The GWA analysis was carried out in the Finnish Genome
Center in Helsinki. A single nucleotide polymorphism (SNP)
genotyping was performed with the commercial release of the
Infinium HumanHap 550 k version 3 chips (Illumina, San Diego,
CA), containing SNPs derived from Phase I and II of the
International HapMap project. Briefly, 750 ng of DNA was used
in genotyping according to the manufacturer’s protocol (Illumina).
Software package PLINK (http://pngu.mgh.harvard.edu/
,purcell/plink/) [34] was used for quality control and
association analysis of the GWA data.
Individual exclusion criteria. Gender calls from X
chromosome genotype data was verified to be in concordance
with the reported gender of each individual. To verify known
familial relationships and to detect not reported first-degree cryptic
relationships, pairwise identity-by-descent analysis was performed.
Individuals with genotyping call rates less than 95% were
excluded, resulting in total of 903 out of 970 samples passing
these criteria. Of these individuals, 869 had the required
phenotype data and these individuals advanced to the actual
association analysis. Total genotyping call rate in remaining
individuals was 99.6%.
Complete linkage agglomerative clustering based on pairwise
identity-by-state (IBS) distance in addition to multidimensional
scaling plots were used to assess population stratification in the
data. Concordance between study center and IBS distances was
observed, and therefore the study center was included in all
statistical models to adjust for population stratification.
Marker exclusion criteria. Markers advanced to the actual
association analysis if they passed the following quality control
criteria 1) had a 95% genotype call rate (4007 markers excluded),
2) had a minor allelic frequency (MAF) .1% (23107 markers
excluded) and 3) demonstrated Hardy-Weinberg Equilibrium with
aP .1e-05 (890 markers excluded). Total of 534 287 markers
passed these quality control criteria. In addition, for each marker,
tests for MAF, Hardy-Weinberg Equilibrium and missingness were
performed, and this information was used when evaluating marker
quality for replication.
Marker imputation. We used Phase 2 HapMap (release 23)
CEU founder population data (60 individuals with MAF.0.01
and genotyping rate .0.95) to impute markers that were not
directly genotyped. PLINK’s discrete genotype calls imputation
with confidence threshold of 0.8 was used for imputation. Same
marker exclusion criteria that were used for filtering directly
genotyped markers were used for imputed markers.
Initial marker screening was directed to the genomic location
indicated by the mouse model (human chromosome 3, 33.2–
33.9 Mb region). After marker exclusion there were 306 markers
located on this region (76 directly genotyped, 230 imputed).
Marker selection for replication studies. We selected the
SNPs for replication on the basis of the most significant P values in
the EUGENE2 GWAS (9 SNPs were selected, arbitrary cut-off
point of P,0.0034 in the EUGENE2 Study). Furthermore, the
genotype distribution of these SNPs had to follow Hardy-
Weinberg expectations, and their MAF was .5%.
METSIM replication study
Subjects and methods. METSIM (METabolic Syndrome
In Men) Study is an ongoing study aiming to include 10 000 men,
aged from 50 to 70 years, randomly selected from the population
register of Kuopio town, Eastern Finland (population of 95 000)
[21]. Every participating subject has one-day outpatient visit to the
University of Kuopio, including an interview on the history of
previous diseases and current drug treatment, and an evaluation of
cardiovascular risk factors. Blood pressure (BP) was measured in a
subject’s sitting position after a 5-minute rest with a mercury
sphygmomanometer. The average of 3 measurements was used to
calculate systolic and diastolic BPs. Height and weight were
measured to the nearest 0.5 cm and 0.1 kg, respectively. Body
mass index was calculated as weight (kg) divided by square of the
height (m). The study protocol was accepted by the Ethics
Committee of the University of Kuopio and Kuopio University
Hospital.
Genotyping. Genotyping was performed using the TaqMan
Allelic Discrimination Assays (Applied Biosystems) or using the
iPLEX Sequenom MassARRAY platform.
RIAD replication study
Subjects and methods. A total of 622 (284 men and 338
women) participants of the RIAD Study, a prospective survey on
the Risk factors in Impaired glucose tolerance for Atherosclerosis
and Diabetes, were included in analysis [22]. In brief, subjects
from 40–70 years of age were examined for those who had risk
factors for the development of T2DM, such as a family history of
T2DM, obesity, and/or hyper/dyslipoproteinemia. Known
diabetes, medication affecting glucose tolerance, liver and kidney
diseases, thyroid gland functional disorders, and acute infections
represented exclusion criteria. Written consent was obtained from
all participants. Subjects aged #55 years were included in the
study (N=237). The study protocol included measurements of BP,
weight, height, and waist circumstance. Systolic and diastolic BPs
were measured in a subject’s sitting position after a 5-minute rest
with a mercury sphygmomanometer. The study was accepted by
the local Ethics Committee.
Genotyping. Genotyping was performed using the TaqMan
Allelic Discrimination Assays (Applied Biosystems).
Association analysis of genotyping results
Association analyses of the genotyping results were carried out
using SPSS 15.0 for Windows (Chicago, IL, USA). Association was
UBP1 as a Critical Blood Pressure Determinant
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with skewed distribution were logarithmically transformed for
statistical analysis. For analysis of EUGENE2 genotyping results,
mixed linear models were used. We included the family (sibship)
and centre as random factors, the sex as a fixed factor, and both
age and BMI as covariates. For analysis of the METSIM and
RIAD genotyping results, linear regression models were used, and
both systolic and diastolic blood pressures were adjusted for
significant covariates (age and BMI for METSIM, and age, BMI
and gender for RIAD). Additive model was used for all analysis.
Effect sizes were calculated in all of the studies by using linear
regression, with non-log transformed BPs as dependent variables.
BPs were adjusted for significant covariates. For both traits the
pooled test of association was determined using fixed model
inverse variance weighted meta-analysis from R’s gap: Genetic
analysis package version 1.0-17 (http://cran.r-project.org/web/
packages/gap/).
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